RGNX News and Press, REGENXBIO Inc. From 03/08/24

2024-03-08 08:30:06 ET Ainos ( AIMD ) +147% . Psyence Biomedical ( PBM ) +104% . CERo Therapeutics ( CERO ) +47% . Gulf Island Fabrication ( GIFI ) +27% on Q4 earnings release . Recruiter.com ( RCRT ) +17% . Porch Group ( P...

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants PR Newswire ROCKVILLE, Md. , March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) a leading clinical-stage biotechnology company seeking to improve lives through...

2024-03-06 16:18:00 ET More on Regenxbio Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio stock jumps 13% on positive data for DMD drug Read the full article on Seeking Alpha For further details see: REGENXBIO stock falls...

REGENXBIO Announces Proposed Public Offering of Common Stock PR Newswire ROCKVILLE, Md. , March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $125,000,000 of its common s...

2024-03-05 11:03:07 ET More on Regenxbio REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio Q4 2023 Earnings Preview Regenxbio spikes after trial win for gene therapy in Hu...

2024-03-05 10:02:11 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...

2024-03-05 08:30:49 ET DENVER, Colo., Mar 05, 2024 ( 247marketnews.com )- REGENXBIO Inc. (NASDAQ: RGNX ) reported, this morning, additional interim safety and efficacy data from its Phase I/II AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne muscular dystrophy ...

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL PR Newswire New three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression Patient aged 12 years at dosing had expression level at 75...

2024-03-04 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial PR Newswire Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. EST Interim clinical data will be presented by Aravindhan Veerapa...